Formosa Laboratories Inc Total Assets
Formosa Laboratories Inc total assets. Based on the latest financial reports, Formosa Laboratories Inc (4746) holds total assets worth NT$13.70 Billion TWD (≈ $431.57 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Formosa Laboratories Inc (4746) cash conversion ratio for how efficiently the company converts equity into cash flow.
Total Assets of Formosa Laboratories Inc (2009–2025)
Total assets of Formosa Laboratories Inc from 2009 to 2025. This chart illustrates how Formosa Laboratories Inc's total assets have evolved over time, based on quarterly financial data. See 4746 share price today for real-time trading data and today's change.
Formosa Laboratories Inc - Asset Composition Analysis
Formosa Laboratories Inc Total Assets Breakdown (December 2025)
Formosa Laboratories Inc total assets breakdown as of December 2025. Formosa Laboratories Inc's total assets of NT$13.70 Billion consist of 40.1% current assets and 59.9% non-current assets. Explore 4746 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.3% |
| Accounts Receivable | NT$1.16 Billion | 8.4% |
| Inventory | NT$1.72 Billion | 12.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$292.71 Million | 2.1% |
| Goodwill | NT$60.40 Million | 0.4% |
Asset Composition Trend (2009–2025)
This chart illustrates how Formosa Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Formosa Laboratories Inc's current assets represent 40.1% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2025, up from 5.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 12.4% of total assets.
Formosa Laboratories Inc Competitors by Total Assets
Key competitors of Formosa Laboratories Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.34 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥7.80 Billion |
|
Northeast Pharmaceutical Group Co Ltd
SHE:000597
|
China | CN¥13.58 Billion |
Formosa Laboratories Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 2.25 | 1.54 |
| Quick Ratio | 1.54 | 1.60 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$3.07 Billion | NT$3.26 Billion | NT$1.26 Billion |
Formosa Laboratories Inc - Advanced Valuation Insights
This section examines the relationship between Formosa Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | NT$13.83 Billion |
| Market Capitalization | $174.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Formosa Laboratories Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Formosa Laboratories Inc's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Formosa Laboratories Inc (2009–2025)
The table below shows the annual total assets of Formosa Laboratories Inc from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$13.83 Billion ≈ $435.83 Million |
-0.45% |
| 2024-12-31 | NT$13.90 Billion ≈ $437.78 Million |
+1.90% |
| 2023-12-31 | NT$13.64 Billion ≈ $429.61 Million |
+6.94% |
| 2022-12-31 | NT$12.75 Billion ≈ $401.72 Million |
+6.11% |
| 2021-12-31 | NT$12.02 Billion ≈ $378.60 Million |
+16.83% |
| 2020-12-31 | NT$10.29 Billion ≈ $324.06 Million |
+7.05% |
| 2019-12-31 | NT$9.61 Billion ≈ $302.72 Million |
+10.12% |
| 2018-12-31 | NT$8.73 Billion ≈ $274.89 Million |
+20.49% |
| 2017-12-31 | NT$7.24 Billion ≈ $228.15 Million |
+7.53% |
| 2016-12-31 | NT$6.73 Billion ≈ $212.17 Million |
+4.31% |
| 2015-12-31 | NT$6.46 Billion ≈ $203.41 Million |
+13.46% |
| 2014-12-31 | NT$5.69 Billion ≈ $179.28 Million |
+14.01% |
| 2013-12-31 | NT$4.99 Billion ≈ $157.24 Million |
+23.67% |
| 2012-12-31 | NT$4.04 Billion ≈ $127.14 Million |
+29.62% |
| 2011-12-31 | NT$3.11 Billion ≈ $98.09 Million |
+31.08% |
| 2010-12-31 | NT$2.38 Billion ≈ $74.83 Million |
+40.36% |
| 2009-12-31 | NT$1.69 Billion ≈ $53.32 Million |
-- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomo… Read more